The Technical Analyst
Select Language :
Hangzhou Tigermed [3347.HK]

Exchange: HKSE Sector: Healthcare Industry: Diagnostics & Research

Hangzhou Tigermed Price, Forecast, Insider, Ratings, Fundamentals & Signals

Hangzhou Tigermed is listed at the  Exchange

-3.37% HKD34.45

America/New_York / 3 mai 2024 @ 04:08


Hangzhou Tigermed: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 44 443 mill
EPS: 2.16
P/E: 15.95
Earnings Date: Apr 25, 2024
SharesOutstanding: 1 290.07 mill
Avg Daily Volume: 2.59 mill
RATING 2024-05-03
A-
Buy
RATINGS
Rating CashFlow: Strong Buy
Return On Equity: Neutral
Return On Asset: Neutral
DE: Neutral
P/E: Buy
Price To Book: Sell
QUARTER GROWTHS
4/221/232/233/234/231/24
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.46x
Company: PE 15.95 | sector: PE 34.76
PE RATIO: COMPANY / INDUSTRY
0.49x
Company: PE 15.95 | industry: PE 32.83
DISCOUNTED CASH FLOW VALUE
HKD96.75
(180.83%) HKD62.30
Date: 2024-05-03
Expected Trading Range (DAY)

HKD 32.23 - 36.77

( +/- 6.59%)
ATR Model: 14 days

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - HKD34.40
Forecast 2: 16:00 - HKD34.40
Forecast 3: 16:00 - HKD34.40
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price HKD34.45 (-3.37% )
Volume 0.715 mill
Avg. Vol. 2.59 mill
% of Avg. Vol 27.58 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Hangzhou Tigermed Consulting Co., Ltd

Last 12 Months

Last 12 months chart data with high, low, open and close for Hangzhou Tigermed Consulting Co., Ltd

RSI

Intraday RSI14 chart for Hangzhou Tigermed Consulting Co., Ltd

Last 10 Buy & Sell Signals For 3347.HK

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            Hangzhou Tigermed Consulting Co., Ltd

3347.HK

Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers regulatory submission and approval, medical translation, and good manufacturing practice (GMP) consulting services; and clinical services in the areas of medical science, early clinical and late phase development, medical monitoring, project management, patient recruitment, and quality management system. It also provides biometrics services comprising data management, biostatistics, and statistical programming; and integrated technology services, such as site management, pharmacovigilance, third party audit and training, medical imaging, clinical trial system solution, central laboratory, pre-clinical, and research hospital. Further, the company offers medical device/ in vitro diagnostics (IVD) services comprising medical device testing, regulatory submission, clinical evaluation and trials, GMP certificate, EU MDR and IVDR preparation, and value-added services; and post-marketing study, real world evidence, and vaccine clinical trial services. Hangzhou Tigermed Consulting Co., Ltd. was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.

Last 10 Buy Signals

Date Signal @
YF-DAIUSDMay 3 - 07:1038.54
YMUSDMay 3 - 07:0138 666
SCHB.OLMay 3 - 06:54NOK322.80
HSHP.OLMay 3 - 06:5291.90
GFARM2USDMay 3 - 07:063 315.34
DPXUSDMay 3 - 07:0528.34
KIT.OLMay 3 - 06:51NOK29.12
LSG.OLMay 3 - 06:50NOK47.66
NAS.OLMay 3 - 06:49NOK14.68
^N100May 3 - 06:51PTS1 504.34

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.